Search

Your search keyword '"Andel J"' showing total 585 results
Start Over Author "Andel J"
585 results on '"Andel J"'

1. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Author

Bachelot, T., Bouzid, K., Campone, M., Desmoulins, I., Coudert, B., Bondarenko, I., Nowecki, Z., Glogowska, I., Ciruelos Gil, E., Errihani, H., Dalenc, F., Ricci, F., Dieras, V., Kaufman, B., Paluch-Shimon, S., Wardley, A., Schneeweiss, A., Ferreira, A., Mano, M., Kalofonos, H., Andreetta, C., Puglisi, F., Montemurro, F., Barrett, S., Zhang, Q., Mavroudis, D., Matus, J., Villarreal Garza, C., Beato, C., Ismael, G., Hu, X., Abdel Azeem, H., Gaafar, R., Perrin, C., Kerbrat, P., Ettl, J., Paepke, S., Hitre, E., Lang, I., Trudeau, M., Verma, S., Li, H., Hoffmann, O., Aktas, B., Cariello, A., Cruciani, G., Tienghi, A., Tondini, C., Al-Twegieri, T., Loman, N., Laing, R., Miles, D., Brain, E., Fasching, P., Lux, M., Frassoldati, A., Aziz, Z., Salas, J., Streb, J., Krzemieniecki, K., Wronski, A., Garcia Garcia, J., Menjon Beltran, S., Cicin, I., Schmid, P., Gallagher, C., Turner, N., Tong, Z., Boer, K., Juhász, B., Horvath, Z., Bianchini, G., Gianni, L., Curigliano, G., Juarez Ramiro, A., Susnjar, S., Matos, E., Sevillano, E., Garcia Estevez, L., Gokmen, E., Uslu, R., Wildiers, H., Schutz, F., Cruz, M., Bourgeois, H., von Schumann, R., Stemmer, S., Dominguez, A., Morales-Vásques, F., Wojtukiewicz, M., Trifunovic, J., Echarri Gonzalez, M.J., Illarramendi Mañas, J., Martinez De Dueñas, E., Voitko, N., Hicks, J., Waters, S., Barrett-Lee, P., Wheatley, D., De Boer, R., Cocquyt, V., Jerusalem, G., Barrios, C., Panasci, L., Mattson, J., Tanner, M., Gozy, M., Vasilopoulos, G., Papandreou, C., Revesz, J., Battelli, N., Benedetti, G., Latini, L., Gridelli, C., Lazaro Leon, J., Alarcón Company, J., Arance Fernandez, A., Barnadas Molins, A., Calvo Plaza, I., Bratos, R., Gonzalez Martin, A., Izarzugaza Peron, Y., Klint, L., Kovalev, A., McCarthy, N., Yeo, B., Kee, D., Thomson, J., White, S., Greil, R., Wang, S., Artignan, X., Juhasz-Böess, I., Rody, A., Ngan, R., Dourleshter, F., Goldberg, H., Doni, L., Di Costanzo, F., Ferraù, F., Drobniene, M., Aleknavicius, E., Rashid, K., Costa, L., de la Cruz Merino, L., Garcia Saenz, J., López, R., Del Val Munoz, O., Ozyilkan, O., Azribi, F., Jaafar, H., Baird, R., Verrill, M., Beith, J., Petzer, A., Moreira de Andrade, J., Bernstein, V., Macpherson, N., Rayson, D., Saad Eldin, I., Achille, M., Augereau, P., Müller, V., Rasco, A., Evron, E., Katz, D., Berardi, R., Cascinu, S., De Censi, A., Gennari, A., El-Saghir, N., Ghosn, M., Oosterkamp, H.M., Van den Bosch, J., Kukulska, M., Kalinka, E., Alonso, J., Dalmau Portulas, E., Del Mar Gordon Santiago, M., Pelaez Fernandez, I., Aksoy, S., Altundag, K., Senol Coskun, H., Bozcuk, H., Shparyk, Y., Barraclough, L., Levitt, N., Panwar, U., Kelly, S., Rigg, A., Varughese, M., Castillo, C., Fein, L., Malik, L., Stuart-Harris, R., Singer, C., Stoeger, H., Samonigg, H., Feng, J., Cedeño, M., Ruohola, J., Berdah, J.-F., Goncalves, A., Orfeuvre, H., Grischke, E.-M., Simon, E., Wagner, S., Koumakis, G., Papazisis, K., Ben Baruch, N., Fried, G., Geffen, D., Karminsky, N., Peretz, T., Cavanna, L., Pedrazzioli, P., Grasso, D., Ruggeri, E., D’Auria, G., Moscetti, L., Juozaityte, E., Rodriguez Cid, J., Roerdink, H., Siddiqi, N., Passos Coelho, J., Arcediano Del Amo, A., Garcia Garre, E., García Gonzalez, M., Garcia-Palomo Perez, A., Herenandez Perez, C., Lopez Alvarez, P., Lopez De Ceballos, M.H., Martínez Jañez, N., Mele Olive, M., McAdam, K., Perren, T., Dunn, G., Humphreys, A., Taylor, W., Vera, R., Kaen, L., Andel, J., Steger, G., De Grève, J., Huizing, M., Hegg, R., Joy, A., Kuruvilla, P., Sehdev, S., Smiljanic, S., Kütner, R., Alexandre, J., Grosjean, J., Laplaige, P., Largillier, R., Maes, P., Martin, P., Pottier, V., Christensen, B., Khandan, F., Lück, H.-J., Zahm, D.-M., Fountzilas, G., Karavasilis, V., Safra, T., Inbar, M., Ryvo, L., Bonetti, A., Seles, E., Giacobino, A., Chavarri Guerra, Y., de Jongh, F., van der Velden, A., van Warmerdam, L., Vrijaldenhoven, S., Smorenburg, C.H., Cavero, M., Andres Conejero, R., Oltra Ferrando, A., Redondo Sanchez, A., Ribelles Entrena, N., Saura Grau, S., Viñas Vilaro, G., Bachmeier, K., Beresford, M., Butt, M., Joffe, J., Poole, C., Woodings, P., Chakraborti, P., Yordi, G., Woodward, N., Nobre, A., Luiz Amorim, G., Califaretti, N., Fox, S., Robidoux, A., Li, E., Li, N., Jiang, J., Soria, T., Padrik, P., Lahdenpera, O., Barletta, H., Dohollou, N., Genet, D., Prulhiere, K., Coeffic, D., Facchini, T., Vieillot, S., Catala, S., Teixeira, L., Hesse, T., Kühn, T., Ober, A., Repp, R., Schröder, W., Pectasides, D., Bodoky, G., Kahan, Z., Jiveliouk, I., Rosengarten, O., Rossi, V., Alabiso, O., Pérez Martínez, M., van de Wouw, A.J., Smok-Kalwat, J., Damasecno, M., Augusto, I., Sousa, G., Saadein, A., Abdelhafiez, N., Abulkhair, O., Antón Torres, A., Corbellas Aparicio, M., Llorente Domenech, R., Florián Jerico, J., Garcia Mata, J., Gil Raga, M., Galan Brotons, A., Llombart Cussac, A., Llorca Ferrandiz, C., Martinez Del Prado, P., Olier Garate, C., Rodriguez Sanchez, C., Sanchez Gomez, R., Santisteban Eslava, M., Soberino, J., Vidal Losada Garcia, M., Soto de Prado, D., Torrego Garcia, J., Vicente Rubio, E., Garcia, M., Murias Rosales, A., Granstam Björneklett, H., Narbe, U., Jafri, M., Rea, D., Newby, J., Jones, A., Westwell, S., Ring, A., Alonso, I., Rodríguez, R., Ciruelos, E., Peretz-Yablonski, T., Merot, J.-L., Trask, P., du Toit, Y., Pena-Murillo, C., Revelant, V., and Klingbiel, D.

Published
2021
Full Text
View/download PDF

2. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study

Author

Kamphuisen, P.W., Lee, A.Y.Y., Meyer, G., Bauersachs, R., Janas, M.S., Jarner, M.F., Khorana, A.A., Bella Santiago, R., Cerana, S., Zarbá, J.J., Andel, J., Barrios, C.H., Borba Reiriz, A., Cesario, F., de Azevedo, S., Ferreira Filho, A.F., Franke, F.A., Padilha, S., Paiva Queiroz, R., Pimenta, A., Rerin, J., Rigo, R., van Eyll Rocha, S.B., Santos Borges, G., Vacaro, G., Anastasov, V., Dragneva, T., Georgiev, G., Champion, P., Kuruvilla, P., Gonzalez, C., Ditl, P., Förster, J., Lubomir, B., Vydra, J., El Hassan, R.A., Sabri, S., Allahloubi, N., Elzawawy, A., Ezzat, S.S., El Kady, M.S., Bacchus, L., Beyer‐Westendorf, J., Kamphausen, U., Niederwieser, D., Ostermann, H., Sosada, M., Anagnostopoulos, N., Fountzilas, G., Ioannou, C., Liapis, C., Schaeffer, J.F.B., Atilli, S., Balsubramanian, S., Bondarde, S., Desai, S.C., Deshmukh, C., Singh, D.P., Gharami, F., Goyal, L., Gupta, S., Gupte, S., Mukherjee, K.K., Krishnan, S., Kumar, K., Mehta, A., Mishra, K., Naik, R., Pawar, S., Nagarkar, R.V., Warrier, N., Brenner, B., Gavish, I., Lugassy, G., Kolin, M., Enrico, B., Mazzucconi, M.G., Visani, G., Awidi, A., Novikovs, N., Miscuks, J., Abigerges, D., Farhat, F., Khoueiry, P., Makarem, J., Alvarez Ordorica, O., Anaya Santacruz, E., Calderillo Ruiz, G., de la Concha Ureta, J.H., Pantigoso, W.S.R., Philco, M., Pineda, A.R., Queszada, E.A.V., Gawrychowski, K., Witkiewicz, W., Macias, E., Teixeira, E., Ciuleanu, T.‐E., Ligia, C.C., Lungulescu, D., Manolescu, I.G., Rodica, A., Volovat, C., Burov, Y., Katelnitsky, I., Svistov, D., Ahmad, K., Algahtani, F., Al‐Zahrani, H., Qari, M., Jovanovic, D., Milanovic, N., Perin, B., Stojanovic, V., Tomasic, L., Chovanec, J., Herman, O., Kissova, V., Sasvary, F., Špánik, S., Szentivanyi, M., Barón, F., Gallardo, E., Jiménez, D., Remedios, O., Sanchez, A., Engelbrecht, J., Jonas, N., McAdam, G., Patel, M., Rapoport, B., Robertson, B., Oh, D., Kim, H., Kim, H.‐K., Kim, H.J., Kim, H.S., Ahn, J.S., Chung, J., Jang, J., Park, K.U., Shin, S.‐W., Kim, S.H., Yoon, S‐S., Kim, Y.‐K., Chiu, C.‐F., Chang, C.‐S., Liu, J.‐H., Rau, K.‐M., Chen, S.‐W., Chittima, S., Ekkapong, T., Nonglak, K., Pantep, A., Pramook, M., Thanakrit, S., Patrapim, S., Sumitra, T., Udomluck, C., Kobza, I., Nykonenko, O., Prasol, V., and Vladychuk, I.

Published
2018
Full Text
View/download PDF

4. Incidence and outcome of acquired demyelinating syndromes in Dutch children: update of a nationwide and prospective study

Author

de Mol, C. L., Wong, Y. Y. M., van Pelt, E. D., Ketelslegers, I. A., Bakker, D. P., Boon, M., Braun, K. P. J., van Dijk, K. G. J., Eikelenboom, M. J., Engelen, M., Geleijns, K., Haaxma, C. A., Niermeijer, J. M. F., Niks, E. H., Peeters, E. A. J., Peeters-Scholte, C. M. P. C. D., Poll-The, B. T., Portier, R. P., de Rijk-van Andel, J. F., Samijn, J. P. A., Schippers, H. M., Snoeck, I. N., Stroink, H., Vermeulen, R. J., Verrips, A., Visscher, F., Vles, J. S. H., Willemsen, M. A. A. P., Catsman-Berrevoets, C. E., Hintzen, R. Q., and Neuteboom, R. F.

Published
2018
Full Text
View/download PDF

5. S179: RANDOMIZED COMPARISON BETWEEN KRD AND KTD INDUCTION, FOLLOWED BY K MAINTENANCE OR OBSERVATION IN TRANSPLANT NON-ELIGIBLE PATIENTS WITH NDMM (AGMT-MM02 TRIAL)

Author

Ludwig, H., primary, Melchardt, T., additional, Sormann, S., additional, Zojer, N., additional, Andel, J., additional, Hartmann, B., additional, Tinchon, C., additional, Gunsilius, E., additional, Podar, K., additional, Egle, A., additional, Willenbacher, W., additional, Wöll, E., additional, Schreder, M., additional, Ruckser, R., additional, Bozic, B, additional, Krauth, M.-T., additional, Petzer, A., additional, Schmitt, C, additional, Machherndl-Spandl, S., additional, Agis, H., additional, Fillitz, M., additional, Pönisch, W., additional, Knop, S., additional, Paiva, B., additional, and Greil, R., additional

Published
2022
Full Text
View/download PDF

6. Hospital variation in treatment patterns and oncological outcomes for patients with muscle-invasive and metastatic bladder cancer in the Netherlands

Author

MS Urologische Oncologie, Cancer, MS Radiotherapie, Reesink, Daan J., van de Garde, Ewoudt M.W., van der Nat, Paul, Somford, Diederik M., Los, Maartje, Horenblas, Simon, van Melick, Harm H.E., Biesma, D. H., Stijns, P. E.F., Lavalaye, J., De Bruin, P. C., Peters, B. J.M., Berends, M., Richardson, R., Van Andel, J., Klaver, O. S., Haberkorn, B. C.M., Van Rooijen, J. M., Korthorst, R. A., Meijer, R. P., Van der Voort Van Zyp, J. R.N., for the Santeon MIBC Study Group, MS Urologische Oncologie, Cancer, MS Radiotherapie, Reesink, Daan J., van de Garde, Ewoudt M.W., van der Nat, Paul, Somford, Diederik M., Los, Maartje, Horenblas, Simon, van Melick, Harm H.E., Biesma, D. H., Stijns, P. E.F., Lavalaye, J., De Bruin, P. C., Peters, B. J.M., Berends, M., Richardson, R., Van Andel, J., Klaver, O. S., Haberkorn, B. C.M., Van Rooijen, J. M., Korthorst, R. A., Meijer, R. P., Van der Voort Van Zyp, J. R.N., and for the Santeon MIBC Study Group

Published
2022

9. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Author

Miles, D., primary, Ciruelos, E., additional, Schneeweiss, A., additional, Puglisi, F., additional, Peretz-Yablonski, T., additional, Campone, M., additional, Bondarenko, I., additional, Nowecki, Z., additional, Errihani, H., additional, Paluch-Shimon, S., additional, Wardley, A., additional, Merot, J.-L., additional, Trask, P., additional, du Toit, Y., additional, Pena-Murillo, C., additional, Revelant, V., additional, Klingbiel, D., additional, Bachelot, T., additional, Bouzid, K., additional, Desmoulins, I., additional, Coudert, B., additional, Glogowska, I., additional, Ciruelos Gil, E., additional, Dalenc, F., additional, Ricci, F., additional, Dieras, V., additional, Kaufman, B., additional, Ferreira, A., additional, Mano, M., additional, Kalofonos, H., additional, Andreetta, C., additional, Montemurro, F., additional, Barrett, S., additional, Zhang, Q., additional, Mavroudis, D., additional, Matus, J., additional, Villarreal Garza, C., additional, Beato, C., additional, Ismael, G., additional, Hu, X., additional, Abdel Azeem, H., additional, Gaafar, R., additional, Perrin, C., additional, Kerbrat, P., additional, Ettl, J., additional, Paepke, S., additional, Hitre, E., additional, Lang, I., additional, Trudeau, M., additional, Verma, S., additional, Li, H., additional, Hoffmann, O., additional, Aktas, B., additional, Cariello, A., additional, Cruciani, G., additional, Tienghi, A., additional, Tondini, C., additional, Al-Twegieri, T., additional, Loman, N., additional, Laing, R., additional, Miles, D., additional, Brain, E., additional, Fasching, P., additional, Lux, M., additional, Frassoldati, A., additional, Aziz, Z., additional, Salas, J., additional, Streb, J., additional, Krzemieniecki, K., additional, Wronski, A., additional, Garcia Garcia, J., additional, Menjon Beltran, S., additional, Cicin, I., additional, Schmid, P., additional, Gallagher, C., additional, Turner, N., additional, Tong, Z., additional, Boer, K., additional, Juhász, B., additional, Horvath, Z., additional, Bianchini, G., additional, Gianni, L., additional, Curigliano, G., additional, Juarez Ramiro, A., additional, Susnjar, S., additional, Matos, E., additional, Sevillano, E., additional, Garcia Estevez, L., additional, Gokmen, E., additional, Uslu, R., additional, Wildiers, H., additional, Schutz, F., additional, Cruz, M., additional, Bourgeois, H., additional, von Schumann, R., additional, Stemmer, S., additional, Dominguez, A., additional, Morales-Vásques, F., additional, Wojtukiewicz, M., additional, Trifunovic, J., additional, Echarri Gonzalez, M.J., additional, Illarramendi Mañas, J., additional, Martinez De Dueñas, E., additional, Voitko, N., additional, Hicks, J., additional, Waters, S., additional, Barrett-Lee, P., additional, Wheatley, D., additional, De Boer, R., additional, Cocquyt, V., additional, Jerusalem, G., additional, Barrios, C., additional, Panasci, L., additional, Mattson, J., additional, Tanner, M., additional, Gozy, M., additional, Vasilopoulos, G., additional, Papandreou, C., additional, Revesz, J., additional, Battelli, N., additional, Benedetti, G., additional, Latini, L., additional, Gridelli, C., additional, Lazaro Leon, J., additional, Alarcón Company, J., additional, Arance Fernandez, A., additional, Barnadas Molins, A., additional, Calvo Plaza, I., additional, Bratos, R., additional, Gonzalez Martin, A., additional, Izarzugaza Peron, Y., additional, Klint, L., additional, Kovalev, A., additional, McCarthy, N., additional, Yeo, B., additional, Kee, D., additional, Thomson, J., additional, White, S., additional, Greil, R., additional, Wang, S., additional, Artignan, X., additional, Juhasz-Böess, I., additional, Rody, A., additional, Ngan, R., additional, Dourleshter, F., additional, Goldberg, H., additional, Doni, L., additional, Di Costanzo, F., additional, Ferraù, F., additional, Drobniene, M., additional, Aleknavicius, E., additional, Rashid, K., additional, Costa, L., additional, de la Cruz Merino, L., additional, Garcia Saenz, J., additional, López, R., additional, Del Val Munoz, O., additional, Ozyilkan, O., additional, Azribi, F., additional, Jaafar, H., additional, Baird, R., additional, Verrill, M., additional, Beith, J., additional, Petzer, A., additional, Moreira de Andrade, J., additional, Bernstein, V., additional, Macpherson, N., additional, Rayson, D., additional, Saad Eldin, I., additional, Achille, M., additional, Augereau, P., additional, Müller, V., additional, Rasco, A., additional, Evron, E., additional, Katz, D., additional, Berardi, R., additional, Cascinu, S., additional, De Censi, A., additional, Gennari, A., additional, El-Saghir, N., additional, Ghosn, M., additional, Oosterkamp, H.M., additional, Van den Bosch, J., additional, Kukulska, M., additional, Kalinka, E., additional, Alonso, J., additional, Dalmau Portulas, E., additional, Del Mar Gordon Santiago, M., additional, Pelaez Fernandez, I., additional, Aksoy, S., additional, Altundag, K., additional, Senol Coskun, H., additional, Bozcuk, H., additional, Shparyk, Y., additional, Barraclough, L., additional, Levitt, N., additional, Panwar, U., additional, Kelly, S., additional, Rigg, A., additional, Varughese, M., additional, Castillo, C., additional, Fein, L., additional, Malik, L., additional, Stuart-Harris, R., additional, Singer, C., additional, Stoeger, H., additional, Samonigg, H., additional, Feng, J., additional, Cedeño, M., additional, Ruohola, J., additional, Berdah, J.-F., additional, Goncalves, A., additional, Orfeuvre, H., additional, Grischke, E.-M., additional, Simon, E., additional, Wagner, S., additional, Koumakis, G., additional, Papazisis, K., additional, Ben Baruch, N., additional, Fried, G., additional, Geffen, D., additional, Karminsky, N., additional, Peretz, T., additional, Cavanna, L., additional, Pedrazzioli, P., additional, Grasso, D., additional, Ruggeri, E., additional, D’Auria, G., additional, Moscetti, L., additional, Juozaityte, E., additional, Rodriguez Cid, J., additional, Roerdink, H., additional, Siddiqi, N., additional, Passos Coelho, J., additional, Arcediano Del Amo, A., additional, Garcia Garre, E., additional, García Gonzalez, M., additional, Garcia-Palomo Perez, A., additional, Herenandez Perez, C., additional, Lopez Alvarez, P., additional, Lopez De Ceballos, M.H., additional, Martínez Jañez, N., additional, Mele Olive, M., additional, McAdam, K., additional, Perren, T., additional, Dunn, G., additional, Humphreys, A., additional, Taylor, W., additional, Vera, R., additional, Kaen, L., additional, Andel, J., additional, Steger, G., additional, De Grève, J., additional, Huizing, M., additional, Hegg, R., additional, Joy, A., additional, Kuruvilla, P., additional, Sehdev, S., additional, Smiljanic, S., additional, Kütner, R., additional, Alexandre, J., additional, Grosjean, J., additional, Laplaige, P., additional, Largillier, R., additional, Maes, P., additional, Martin, P., additional, Pottier, V., additional, Christensen, B., additional, Khandan, F., additional, Lück, H.-J., additional, Zahm, D.-M., additional, Fountzilas, G., additional, Karavasilis, V., additional, Safra, T., additional, Inbar, M., additional, Ryvo, L., additional, Bonetti, A., additional, Seles, E., additional, Giacobino, A., additional, Chavarri Guerra, Y., additional, de Jongh, F., additional, van der Velden, A., additional, van Warmerdam, L., additional, Vrijaldenhoven, S., additional, Smorenburg, C.H., additional, Cavero, M., additional, Andres Conejero, R., additional, Oltra Ferrando, A., additional, Redondo Sanchez, A., additional, Ribelles Entrena, N., additional, Saura Grau, S., additional, Viñas Vilaro, G., additional, Bachmeier, K., additional, Beresford, M., additional, Butt, M., additional, Joffe, J., additional, Poole, C., additional, Woodings, P., additional, Chakraborti, P., additional, Yordi, G., additional, Woodward, N., additional, Nobre, A., additional, Luiz Amorim, G., additional, Califaretti, N., additional, Fox, S., additional, Robidoux, A., additional, Li, E., additional, Li, N., additional, Jiang, J., additional, Soria, T., additional, Padrik, P., additional, Lahdenpera, O., additional, Barletta, H., additional, Dohollou, N., additional, Genet, D., additional, Prulhiere, K., additional, Coeffic, D., additional, Facchini, T., additional, Vieillot, S., additional, Catala, S., additional, Teixeira, L., additional, Hesse, T., additional, Kühn, T., additional, Ober, A., additional, Repp, R., additional, Schröder, W., additional, Pectasides, D., additional, Bodoky, G., additional, Kahan, Z., additional, Jiveliouk, I., additional, Rosengarten, O., additional, Rossi, V., additional, Alabiso, O., additional, Pérez Martínez, M., additional, van de Wouw, A.J., additional, Smok-Kalwat, J., additional, Damasecno, M., additional, Augusto, I., additional, Sousa, G., additional, Saadein, A., additional, Abdelhafiez, N., additional, Abulkhair, O., additional, Antón Torres, A., additional, Corbellas Aparicio, M., additional, Llorente Domenech, R., additional, Florián Jerico, J., additional, Garcia Mata, J., additional, Gil Raga, M., additional, Galan Brotons, A., additional, Llombart Cussac, A., additional, Llorca Ferrandiz, C., additional, Martinez Del Prado, P., additional, Olier Garate, C., additional, Rodriguez Sanchez, C., additional, Sanchez Gomez, R., additional, Santisteban Eslava, M., additional, Soberino, J., additional, Vidal Losada Garcia, M., additional, Soto de Prado, D., additional, Torrego Garcia, J., additional, Vicente Rubio, E., additional, Garcia, M., additional, Murias Rosales, A., additional, Granstam Björneklett, H., additional, Narbe, U., additional, Jafri, M., additional, Rea, D., additional, Newby, J., additional, Jones, A., additional, Westwell, S., additional, Ring, A., additional, Alonso, I., additional, and Rodríguez, R., additional

Published
2021
Full Text
View/download PDF

10. 283P Treatment landscape of HER2-positive metastatic breast cancer (MBC): Results from the Austrian AGMT_MBC-Registry

Author

Gampenrieder, S.P., primary, Rinnerthaler, G., additional, Tinchon, C., additional, Petzer, A.L., additional, Balic, M., additional, Heibl, S., additional, Zabernigg, A., additional, Egle, D., additional, Sandholzer, M., additional, Roitner, F., additional, Andel, J., additional, Pichler, P., additional, Hager, C., additional, Hubalek, M., additional, Knauer, M., additional, Singer, C.F., additional, and Greil, R., additional

Published
2021
Full Text
View/download PDF

20. Clinical and genetic aspects of PCDH19-related epilepsy syndromes and the possible role of PCDH19 mutations in males with autism spectrum disorders

Author

van Harssel, J. J. T., Weckhuysen, S., van Kempen, M. J. A., Hardies, K., Verbeek, N. E., de Kovel, C. G. F., Gunning, W. B., van Daalen, E., de Jonge, M. V., Jansen, A. C., Vermeulen, R. J., Arts, W. F. M., Verhelst, H., Fogarasi, A., de Rijk-van Andel, J. F., Kelemen, A., Lindhout, D., De Jonghe, P., Koeleman, B. P. C., Suls, A., and Brilstra, E. H.

Published
2013
Full Text
View/download PDF

21. Prognostic factors for relapse and outcome in pediatric acute transverse myelitis

Author

Helfferich, Jelte, Bruijstens, Arlette L., Wong, Yu Yi M., Danielle van Pelt, E., Boon, Maartje, Neuteboom, Rinze F., Bakker, D. P., Braun, K. P.J., van Dijk, K. G.J., Eikelenboom, M. J., Engelen, M., Brandsma, R., Haaxma, C. A., Niermeijer, J. M.F., Niks, E. H., Peeters, E. A.J., Peeters-Scholte, C. M.P.C.D., Portier, R. P., de Rijk-van Andel, J. F., Samijn, J. P.A., Schippers, H. M., Sie, L. T.L., Snoeck, I. N., Vermeulen, R. J., Verrips, A., Visscher, F., Willemsen, M. A.A.P., Catsman-Berrevoets, C. E., Helfferich, Jelte, Bruijstens, Arlette L., Wong, Yu Yi M., Danielle van Pelt, E., Boon, Maartje, Neuteboom, Rinze F., Bakker, D. P., Braun, K. P.J., van Dijk, K. G.J., Eikelenboom, M. J., Engelen, M., Brandsma, R., Haaxma, C. A., Niermeijer, J. M.F., Niks, E. H., Peeters, E. A.J., Peeters-Scholte, C. M.P.C.D., Portier, R. P., de Rijk-van Andel, J. F., Samijn, J. P.A., Schippers, H. M., Sie, L. T.L., Snoeck, I. N., Vermeulen, R. J., Verrips, A., Visscher, F., Willemsen, M. A.A.P., and Catsman-Berrevoets, C. E.

Abstract

Objective: It may be difficult for clinicians to estimate the prognosis of pediatric acute transverse myelitis (ATM). The aim of this study was to define prognostic factors for relapsing disease and poor outcome in pediatric ATM. Methods: This prospective cohort study included 49 children, 18 boys and 31 girls (median age 13.1 years, IQR 6.5–16.2) with a first episode of ATM. Factors associated with relapsing disease and poor outcome (Expanded Disability Status Scale (EDSS) ≥ 4) were assessed during a median follow-up of 37 months (IQR 18–75). Results: In total, 14 patients (29%) experienced ≥ 1 relapse(s) and nine patients (18%) had a poor outcome. Factors at onset associated with relapsing disease included higher age (16.1 vs. 11.6 years, p = 0.002), longer time to maximum severity of symptoms (5.5 vs. 3 days, p = 0.01), lower maximum EDSS score (4.0 vs. 6.5, p = 0.003), short lesion on spinal MRI (64 vs. 21%, p = 0.006), abnormalities on brain MRI (93 vs. 44%, p = 0.002) and presence of oligoclonal bands in cerebrospinal fluid (67 vs. 14%, p = 0.004). The only factor associated with poor outcome was presence of a spinal cord lesion on MRI without cervical involvement (56 vs. 14%, p = 0.02). Conclusion: Pediatric ATM patients presenting with clinical, radiological and laboratory features associated with multiple sclerosis (MS) are at risk for relapsing disease. In absence of these known MS risk factors at onset of disease these patients are at low risk for relapses. Only a minority of pediatric ATM patients in this cohort have a poor outcome.

Published
2021

22. Prognostic factors for relapse and outcome in pediatric acute transverse myelitis

Author

Neurologen, Brain, Helfferich, Jelte, Bruijstens, Arlette L., Wong, Yu Yi M., Danielle van Pelt, E., Boon, Maartje, Neuteboom, Rinze F., Bakker, D. P., Braun, K. P.J., van Dijk, K. G.J., Eikelenboom, M. J., Engelen, M., Brandsma, R., Haaxma, C. A., Niermeijer, J. M.F., Niks, E. H., Peeters, E. A.J., Peeters-Scholte, C. M.P.C.D., Portier, R. P., de Rijk-van Andel, J. F., Samijn, J. P.A., Schippers, H. M., Sie, L. T.L., Snoeck, I. N., Vermeulen, R. J., Verrips, A., Visscher, F., Willemsen, M. A.A.P., Catsman-Berrevoets, C. E., Neurologen, Brain, Helfferich, Jelte, Bruijstens, Arlette L., Wong, Yu Yi M., Danielle van Pelt, E., Boon, Maartje, Neuteboom, Rinze F., Bakker, D. P., Braun, K. P.J., van Dijk, K. G.J., Eikelenboom, M. J., Engelen, M., Brandsma, R., Haaxma, C. A., Niermeijer, J. M.F., Niks, E. H., Peeters, E. A.J., Peeters-Scholte, C. M.P.C.D., Portier, R. P., de Rijk-van Andel, J. F., Samijn, J. P.A., Schippers, H. M., Sie, L. T.L., Snoeck, I. N., Vermeulen, R. J., Verrips, A., Visscher, F., Willemsen, M. A.A.P., and Catsman-Berrevoets, C. E.

Published
2021

23. Incidence of acquired demyelinating syndromes of the CNS in Dutch children: a nationwide study

Author

Ketelslegers, I. A., Catsman-Berrevoets, C. E., Neuteboom, R. F., Boon, M., van Dijk, K. G. J., Eikelenboom, M. J., Gooskens, R. H. J. M., Niks, E. H., Overweg-Plandsoen, W. C. G., Peeters, E. A. J., Peeters-Scholte, C. M. P. C. D., Poll-The, B. T., de Rijk-van Andel, J. F., Samijn, J. P. A., Snoeck, I. N., Stroink, H., Vermeulen, R. J., Verrips, A., Vles, J. S. H., Willemsen, M. A. A. P., Rodrigues Pereira, R., and Hintzen, R. Q.

Published
2012
Full Text
View/download PDF

25. Hospital variation in treatment patterns and oncological outcomes for patients with muscle-invasive and metastatic bladder cancer in the Netherlands.

Author

Reesink, Daan J., van de Garde, Ewoudt M. W., van der Nat, Paul, Somford, Diederik M., Los, Maartje, Horenblas, Simon, van Melick, Harm H. E., for the Santeon MIBC Study Group, Biesma, D. H., Stijns, P. E. F., Lavalaye, J, De Bruin, P. C., Peters, B. J. M., Berends, M, Richardson, R, Van Andel, J, Klaver, O. S., Haberkorn, B. C. M., Van Rooijen, J. M., and Korthorst, R. A.

Subjects
CANCER patients, BLADDER cancer, METASTASIS, TREATMENT effectiveness, INDUCTION chemotherapy, ONCOLOGY nursing, ONCOLOGISTS
Abstract

Purpose: Population-based studies on treatment patterns in oncology and corresponding clinical outcomes can help identify strategies towards optimal value for patients. This study was performed to describe the variation in treatment patterns and major oncological outcomes for muscle-invasive or metastatic bladder cancer (MIBC/mBC) patients in the Netherlands. Methods: Patients diagnosed with cT2-4aN0-3M0-1 disease between 2008 and 2016 in seven large teaching hospitals in the Netherlands were included. Baseline characteristics, disease stage, intended and definitive treatment, and oncological outcomes were collected. Patients were categorized based on cTNM-stage: (1) cT2-4aN0M0, (2) cT2-4aN1-3M0 and (3) cT4b and/or M1. Results: The total study population comprised 1853 patients, of which 1303 patients were diagnosed with cT2-4aN0M0 disease. Overall, curative treatment was intended in 81% (range 74–85%, P value = 0.132). Radical cystectomy (RC) and curative radiotherapy (RTx) ranged between hospitals from 42 to 66% and 13 to 27%, respectively (P value < 0.001). For 334 patients staged cT4b and/or M1, frequencies for palliative therapy and best supportive care (no anti-cancer therapy) ranged between hospitals from 20 to 54% and 44 to 71%, respectively (P value < 0.001). There was no association between hospital site and overall survival (OS) in a univariable and multivariable Cox regression for survival analysis (after adjusting for age and cT-stage), for all three cTNM-groups. Neoadjuvant or induction chemotherapy (NAIC) utilization rates before RC ranged from 8 to 38% (P value < 0.001). Conclusions: There is large inter-hospital variation in treatment intent in MIBC/mBC patients. This variation does not seem to translate to differences in overall survival rates. There is an ongoing trend of increased use of RC. Utilisation of NAIC is relatively low considering European guideline recommendations. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. Local and central evaluation of HER2 positivity and clinical outcome in advanced gastric and gastroesophageal cancer: results from the AGMT GASTRIC-5 Registry

Author

Huemer, F., Weiss, L., Regitnig, P., Winder, T., Hartmann, B., Thaler, J., Piringer, G., Schmitt, C.A., Eisterer, W., Gänzer, H., Wüstner, Al., Andel, J., Jagdt, B., Ulmer, H., Greil, R., and Wöll, E.

Subjects
Cancer Research
Abstract

Trastuzumab in combination with a platinum and fluorouracil is the treatment of choice for patients with advanced human epidermal growth factor receptor 2 (HER2) positive gastric cancer and gastroesophageal junction (GEJ) cancer. Pathological assessment of the HER2 status in gastric/GEJ cancer, however, still remains difficult. However, it is a crucial prerequisite for optimal treatment. The GASTRIC-5 registry was designed as an observational, multi-center research initiative comparing local and central HER2 testing. HER2 status was assessed by immunohistochemistry (IHC) and in equivocal cases (IHC score 2+) by additional in-situ hybridization. Between May 2011 and August 2018, tumor samples of 183 patients were tested in local and central pathology laboratories, respectively. Central testing revealed HER2 positivity in 38 samples (21%). Discordant HER2 results were found in 12% (22 out of 183) with locally HER2 positive/centrally HER2 negative results (9%, 17 out of 183), exceeding locally HER2 negative/centrally HER2 positive results (3%, 5 out of 183). Centrally confirmed HER2 positive patients receiving trastuzumab-based palliative first-line therapy showed a longer median overall survival compared to centrally HER2 positive patients not receiving trastuzumab (17.7 months (95% CI: 10,870-24,530) vs. 6.9 months (95% CI: 3.980-9.820), p = 0.016). The findings of the GASTRIC-5 registry corroborate the challenge of HER2 testing in gastric/GEJ cancer and highlight the necessity for central quality control to optimize individual treatment options. Centrally HER2 positive patients not receiving trastuzumab had the worst outcome in a Western real-world gastric/GEJ cancer cohort.

Published
2020

27. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings†

Author

Kubicka, S., Greil, R., André, T., Bennouna, J., Sastre, J., Van Cutsem, E., von Moos, R., Österlund, P., Reyes-Rivera, I., Müller, T., Makrutzki, M., Arnold, D., Andel, J, Balcke, P, Benedicic, B, Eisterer, W, Fridrik, M, Jagdt, B, Keil, F, Kretschmer, A, Krippl, P, Oexle, H, Pecherstorfer, M, Samonigg, H, Schmid, M, Thaler, J, Tinchon, C, Weiss, H., Arts, J, De Man, M, Demolin, G, Janssens, J, Polus, M., Benczikova, B, Melichar, B, Prausova, J, Vitek, P., Andersen, FZ, Jensen, BB, Keldsen, N, Østerlind, K, Vistisen, K., Elme, A, Magi, A, Ojamaa, K., Ristamäki, R, Salminen, T., Ben Abdelghani, M, Bouche, O, Borg, C, Bouhier-Leporrier, K, Breysacher, G, Chone, L, Clavero Fabri, M-C, Deplanque, G, Desseigne, F, Dourthe, L-M, Ezenfis, J, Faroux, R, François, E, Garnier, C, Gaspard, M-H, Hebbar, M, Illory, JF, Kaminsky, M-C, Lecomte, T, Legoux, J-L, Levache, B, Lobry, C, Lotz, J-P, Mabro, M, Manet-Lacombe, S, Manfredi, S, Matysiak Budnik, T, Miglianico, L, Mineur, L, Moullet, I, Naman, H, Nouyrigat, P, Oziel-Taieb, S, Perrier, H, Pezet, D, Philip, J, Pottier, V, Porneuf, M, Ramdani, M, Re, D, Rinaldi, Y, Spaeth, D, Taieb, J, Terrebonne, E, Texereau, P, Thirot Bidault, A, Tournigand, C, Tubiana-Mathieu, N, Vantelon, J-M, Viret, F, Ychou, M., Bangerter, M, Bertram, ME, Bohnsteen, B, Brinkmann, L, Caca, K, Constantin, C, Cordes, H-J, Dietrich, G, Eggert, J, Engel, E, Fahlke, J, Fensterer, H, Florschütz, A, Folprecht, G, Forstbauer, H, Freier, W, Freund, M, Frickhofen, N, Gäbele, E, Geiler, M, Gieseler, F, Göhler, T, Graeven, U, Groschek, M, Grundeis, M, Hacker, U, Hagen, V, Hebart, HF, Hegewisch-Becker, S, Heike, M, Herrmann, T, Hildebrandt, B, Höffkes, H-G, Hübner, G, Hübner, J, Kettner, E, Kneba, M, Kohnke, JW, Kojouharoff, G, König, C, Kretzschmar, A, Kröning, H, Kürner, K, Lammert, F, Lerchenmüller, C, Lück, A, Meiler, J, Mergenthaler, H-G, Müller, L, Müller-Naendrup, C, Nusch, A, Papke, J, Porschen, R, Rädle, J, Reddemann, C, Ridwelski, K, Riera-Knorrenschild, J, Rudi, J, Schmalenberger, A, Schimanski, C-C, Schlegel, F, Schlichting, C, Schmidt, P, Schmiegel, W, Schmitz, S, Schulze-Bergkamen, H, Schwaner, I, Schwarzer, A, Schwerdtfeger, M, Selbach, J, Sieber, M, Siebler, J, Staib, P, Stauch, M, Steffens, C-C, Stübs, P, Tischendorf, J, Trarbach, T, Tummes, D, Valdix, A-R, Vogel, A, Von Wichert, GPL, Walther, M, Welslau, W, Wilhelm, G, Wobster, H, Wolf, T, Zeigenhagen, N, Zomorodbaksch, B., Batman, E, Bloemendal, HJ, Kehrer, DFS., Guren, T, Indrebø, G, Kersten, C, Soerbye, H., Fragoso, M, Fragoso, R, Mellidez, JC, Sa, A., Aljobran, A, Darwish, T., Alonso-Orduna, V, Aparicio, J, Aranda, E, Bosch, C, Galan-Brotons, A, Busquier Hernandez, I, Camara, JC, Campos Cervera, JM, Carlos Garcia Giron, C, Del Prado, PM, Donnay, O, Escudero, P, Falco, E, Gallego Plazas, J, Garcia Alfonso, P, Gonzalez Flores, E, Gravalos, C, Guardeno, R, Juárez, A, Lopez Ladron, A, Losa Gaspa, F, MVicent Vergé, J, Marcuello Gaspar, E, Massuti Sureda, B, Molina, J, Montero, IC, Muñoa, AL, Naranjo, MB, Oruezabal Moreno, MJ, Pachón Olmos, V, Pericay, C, Reina Zoilo, JJ, Rivera, F, Ruiz Casado, A, Safont, MJ, Salud Salvia, A, Tobena, M, Toral, JC, Valenti, V, Valladares Ayerbes, M, Vieitez, JM, Vera, R, Vieitez, JM., Berglund, A, Fernebro, E., Hess-Umbricht, V, Pless, M, Popescu, R, and Winterhalder, R.

Published
2013
Full Text
View/download PDF

33. Roadmap Sociale Innovatie Topsector Logistiek: Sociale Innovatie aanjagen, ontwikkelen en opschalen: Voor een toekomstbestendige logistiek

Author

Preenen, P., Vos, M., Andel, J. van, Heus, Y. de, Maarel, R. van der, and Dhondt, S.

Subjects
Logistiek, Bedrijven, Sociale innovatie, Scholing, Werknemers
Abstract

Dit document beschrijft een gezamenlijke, gecoördineerde visie en aanpak ter bevordering van Sociale Innovatie (SI) bij logistieke bedrijven voor een duurzame, aantrekkelijke en excellente logistieke sector. Daartoe is een solide, breed gedragen, en concreet actieprogramma (roadmap) ontwikkeld met onderzoeks-, innovatie- en implementatieprojecten voor de periode medio 2018-2023, de roadmap Sociale Innovatie. Deze roadmap heeft als doel om op onderbouwde wijze kennis te ontwikkelen en richting te geven aan SI in de logistiek, maar bovenal om tot gefocuste en gezamenlijke actie aan te zetten. Hierdoor zorgen we dat SI echt gaat werken voor de bedrijven en de sector en helpt om de hedendaagse en toekomstige uitdagingen te lijf te gaan. De SI-roadmap draagt bij aan: 1. het kunnen opvangen van het (groeiende) tekort aan logistieke professionals voor alle opleidingsniveaus; 2. het voorkomen van uitstroom door mensen op niveau te houden, uit te dagen en het werken in de sector aantrekkelijk en veilig te houden; 3. het ‘slimmer’ werken en kunnen meebewegen met de veranderende (technologische, maatschappelijke) eisen van werken in de logistiek. Dit vergt een andere mindset en an-dere skills van medewerkers, een andere opstelling van leidinggevenden, maar ook on-dersteuning vanuit de organisatie door het inrichten van leerrijke werkplekken; 4. het beter benutten en laten renderen van technologische innovaties. Technologieën worden onvoldoende ingezet bij logistieke bedrijven. Initiatieven eindigen in de startfase, vinden ‘versnipperd’ plaats, of verzanden; 5. organisatie- en gedragsveranderingen gericht op verduurzaming van de logistieke sector; 6. het creëren van verbinding tussen bedrijven, overheid, onderzoeksinstellingen en onderwijs, bijvoorbeeld op het gebied van delen van faciliteiten, kennis, personeel en data.

Published
2019

34. Multimodal nocturnal seizure detection in a residential care setting : A long-term prospective trial

Author

Arends, J., Thijs, R.D., Gutter, T., Ungureanu, C., Cluitmans, P., Dijk, J. van, Andel, J. van, Tan, F., Weerd, A. de, Vledder, B., Hofstra, W., Lazeron, R., Thiel, G. van, Roes, K.C., Leijten, F., Dutch Tele Epilepsy Consortium, Signal Processing Systems, and Biomedical Diagnostics Lab

Subjects
Adult, Male, 0301 basic medicine, Pediatrics, medicine.medical_specialty, Adolescent, Photoplethysmography/instrumentation, Intellectual Disability/complications, Residential Facilities, Cohort Studies, Wearable Electronic Devices, Young Adult, 03 medical and health sciences, Epilepsy, 0302 clinical medicine, Seizures/diagnosis, Heart rate, Humans, Medicine, Prospective Studies, Young adult, Prospective cohort study, Epilepsy/complications, Aged, business.industry, Reproducibility of Results, Accelerometry/instrumentation, Middle Aged, medicine.disease, Confidence interval, Clinical trial, 030104 developmental biology, Movement/physiology, Female, Neurology (clinical), Epileptic seizure, medicine.symptom, Sleep, business, Heart Rate/physiology, 030217 neurology & neurosurgery, Cohort study
Abstract

ObjectiveTo develop and prospectively evaluate a method of epileptic seizure detection combining heart rate and movement.MethodsIn this multicenter, in-home, prospective, video-controlled cohort study, nocturnal seizures were detected by heart rate (photoplethysmography) or movement (3-D accelerometry) in persons with epilepsy and intellectual disability. Participants with >1 monthly major seizure wore a bracelet (Nightwatch) on the upper arm at night for 2 to 3 months. Major seizures were tonic-clonic, generalized tonic >30 seconds, hyperkinetic, or others, including clusters (>30 minutes) of short myoclonic/tonic seizures. The video of all events (alarms, nurse diaries) and 10% completely screened nights were reviewed to classify major (needing an alarm), minor (needing no alarm), or no seizure. Reliability was tested by interobserver agreement. We determined device performance, compared it to a bed sensor (Emfit), and evaluated the caregivers’ user experience.ResultsTwenty-eight of 34 admitted participants (1,826 nights, 809 major seizures) completed the study. Interobserver agreement (major/no major seizures) was 0.77 (95% confidence interval [CI] 0.65–0.89). Median sensitivity per participant amounted to 86% (95% CI 77%–93%); the false-negative alarm rate was 0.03 per night (95% CI 0.01–0.05); and the positive predictive value was 49% (95% CI 33%–64%). The multimodal sensor showed a better sensitivity than the bed sensor (n = 14, median difference 58%, 95% CI 39%–80%, p < 0.001). The caregivers' questionnaire (n = 33) indicated good sensor acceptance and usability according to 28 and 27 participants, respectively.ConclusionCombining heart rate and movement resulted in reliable detection of a broad range of nocturnal seizures.

Published
2018

41. Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: Results from the AGMT_MBC-registry

Author

Gampenrieder, S.P.P., primary, Rinnerthaler, G., additional, Petzer, A., additional, Tinchon, C., additional, Fuchs, D., additional, Balic, M., additional, Heibl, S., additional, Rumpold, H., additional, Egle, D., additional, Zabernigg, A.F., additional, Singer, C.F., additional, Andel, J., additional, Hubalek, M., additional, Knauer, M., additional, and Greil, R., additional

Published
2019
Full Text
View/download PDF

42. The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an Austrian multicenter, non-interventional study

Author

Riedl, J., primary, Posch, F., additional, Prager, G., additional, Eisterer, W., additional, Öhler, L., additional, Thamer, S., additional, Wilthoner, K., additional, Petzer, A., additional, Pichler, P., additional, Hubmann, E., additional, Winder, T., additional, Burgstaller, S., additional, Korger, M., additional, Andel, J., additional, Greil, R., additional, Pecherstorfer, M., additional, Philipp-Abbrederis, K., additional, Djanani, A., additional, Gruenberger, B., additional, Längle, F., additional, Wöll, E., additional, and Gerger, A., additional

Published
2019
Full Text
View/download PDF

45. Incidence and outcome of acquired demyelinating syndromes in Dutch children: update of a nationwide and prospective study

Author

de Mol, C.L. (C. L.), Wong, Y.Y.M. (Yu Yi), Pelt - Gravesteijn, E.D. (Daniëlle) van, Ketelslegers, I.A. (Immy), Bakker, D.P. (Dewi), Boon, M. (Martin), Braun, K.P.J. (Kees P.), Dijk, K.G.J. (K. G J) van, Eikelenboom, M.J. (Merijn Judith), Engelen, M. (Marc), Geleijns, K. (Karin), Haaxma, C.A. (Charlotte A.), Niermeijer, J.M.F. (J. M.F.), Niks, E.H. (Erik), Peeters, E.A. (Els), Peeters-Scholte, C.M.P.C.D. (Cacha), Poll-The, B.T., Portier, R.P. (R. P.), De Rijk-Van Andel, J. (Johanneke), Samijn, J.P. (Johnny), Schippers, H.M., Snoeck, M.M.J. (M. M J), Stroink, H. (Hans), Vermeulen, R.J. (Jeroen), Verrips, A. (Aad), Visscher, F. (F.), Vles, J.S.H. (Johannes), Willemsen, M.A. (Michél), Catsman-Berrevoets, C.E. (Coriene), Hintzen, R.Q. (Rogier), Neuteboom, R.F. (Rinze), de Mol, C.L. (C. L.), Wong, Y.Y.M. (Yu Yi), Pelt - Gravesteijn, E.D. (Daniëlle) van, Ketelslegers, I.A. (Immy), Bakker, D.P. (Dewi), Boon, M. (Martin), Braun, K.P.J. (Kees P.), Dijk, K.G.J. (K. G J) van, Eikelenboom, M.J. (Merijn Judith), Engelen, M. (Marc), Geleijns, K. (Karin), Haaxma, C.A. (Charlotte A.), Niermeijer, J.M.F. (J. M.F.), Niks, E.H. (Erik), Peeters, E.A. (Els), Peeters-Scholte, C.M.P.C.D. (Cacha), Poll-The, B.T., Portier, R.P. (R. P.), De Rijk-Van Andel, J. (Johanneke), Samijn, J.P. (Johnny), Schippers, H.M., Snoeck, M.M.J. (M. M J), Stroink, H. (Hans), Vermeulen, R.J. (Jeroen), Verrips, A. (Aad), Visscher, F. (F.), Vles, J.S.H. (Johannes), Willemsen, M.A. (Michél), Catsman-Berrevoets, C.E. (Coriene), Hintzen, R.Q. (Rogier), and Neuteboom, R.F. (Rinze)

Abstract

Introduction: Acquired demyelinating syndromes (ADS) are immune-mediated demyelinating disorders of the central nervous system in children. A nationwide, multicentre and prospective cohort study was initiated in the Netherlands in 2006, with a reported ADS incidence of 0.66/100,000 per year and MS incidence of 0.15/100,000 per year in the period between 2007 and 2010. In this study, we provide an update on the incidence and the long-term follow-up of ADS in the Netherlands. Methods: Children < 18 years with a first attack of demyelination were included consecutively from January 2006 to December 2016. Diagnoses were based on the International Paediatric MS study group consensus criteria. Outcome data were collected by neurological and neuropsychological assessments, and telephone call assessments. Results: Between 2011 and 2016, 55/165 of the ADS patients were diagnosed with MS (33%). This resulted in an increased ADS and MS incidence of 0.80/100,000 per year and 0.26/100,000 per year, respectively. Since 2006 a total of 243 ADS patients have been included. During follow-up (median 55 months, IQR 28–84), 137 patients were diagnosed with monophasic disease (56%), 89 with MS (37%) and 17 with multiphasic disease other than MS (7%). At least one form of residual deficit including cognitive impairment was observed in 69% of all ADS patients, even in monophasic ADS. An Expanded Disability Status Scale score of ≥ 5.5 was reached in 3/89 MS patients (3%). Conclusion: The reported incidence of ADS in Dutch children has increased since 2010. Residual deficits are common in this group, even in monophasic patients. Therefore, long-term follow-up in ADS patients is warranted.

Published
2018
Full Text
View/download PDF

46. Austrian real world data in elderly and younger metastatic pancreatic cancer patients: Interim results of a multicenter non-interventional study with nab-paclitaxel/gemcitabine

Author

Eisterer, W., primary, Gerger, A., additional, Öhler, L., additional, Mlineritsch, B., additional, Sliwa, T., additional, Wilthoner, K., additional, Petzer, A., additional, Pichler, P., additional, Hubmann, E., additional, Winder, T., additional, Burgstaller, S., additional, Korger, M., additional, Andel, J., additional, Wöll, E., additional, Neumann, H., additional, Pecherstorfer, M., additional, Philipp-Abbrederis, K., additional, Djanani, A., additional, Gruenberger, B., additional, Längle, F., additional, and Prager, G., additional

Published
2018
Full Text
View/download PDF

47. Real-World multicenter Austrian analysis of the safety and effectiveness of nab-paclitaxel in young and elderly patients with metastatic breast cancer

Author

Steger, G., primary, Petru, E., additional, Haslbauer, F., additional, Marth, C., additional, Egle, D., additional, Galid, A., additional, Sliwa, T., additional, Lang, A., additional, Kuehr, T., additional, Petzer, A., additional, Ruckser, R., additional, Greil, R., additional, Mlineritsch, B., additional, Singer, C., additional, Seifert, M., additional, Andel, J., additional, Kwasny, W., additional, Pichler, P., additional, Tinchon, C., additional, and Bartsch, R., additional

Published
2018
Full Text
View/download PDF

48. Epilogue

Author

Van Andel, J., Bakker, J. P., Snaydon, R. W., Werger, M. J. A., editor, Van Andel, J., editor, Bakker, J. P., editor, and Snaydon, R. W., editor

Published
1987
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results